sphingotec GmbH

The Company

sphingotec GmbH develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions, such as acute heart failure, acute kidney injury and circulatory shock, in order to support patient management and provide guidance for treatment strategies. Furthermore, sphingotec develops biomarkers for the prediction of health risks, such as obesity, cardiovascular diseases and breast cancer, in order to support prevention strategies.

sphingotec GmbH was established in 2002 and is located in Hennigsdorf near Berlin, Germany. CEO Dr. Andreas Bergmann was one of the founders of B.R.A.H.M.S. AG. As former Chief Research Officer, he was responsible for the development of the “gold standard” sepsis biomarker Procalcitonin (B.R.A.H.M.S. PCT™).

For further information please follow: www.sphingotec.com


Dr. rer. nat. Andreas Bergmann
Chief Executive Officer

Andreas Bergmann has shaped the diagnostic industry for over 25 years. With an outstanding track record, he has spearheaded the discovery, validation and the development of blood biomarkers. Bergmann was one of the founders and managers of B.R.A.H.M.S. AG where the sepsis marker Procalcitonin (PCT®) was developed under his responsibility as Chief Research Officer. B.R.A.H.M.S. AG started as a management buy-out with 180 employees 1994 and grew to approx. 400 employees by 2009. The biomarker Procalcitonin created a new diagnostic standard of care supporting patient management in sepsis. Andreas Bergmann is inventor, holding over 120 patent rights, and co-author of over 150 peer-reviewed scientific publications.

Bergmann went on to establish sphingotec which is located in Hennigsdorf, near Berlin. Here, he leads the development of innovative biomarkers for prediction, prevention and early intervention strategies in the fields of cancer, cardiovascular diseases and acute care.

Bergmann studied biochemistry at the Freie Universität Berlin and later obtained a PhD in biochemistry at the Technische Universität Berlin in 1987. Before co-founding B.R.A.H.M.S. AG he worked for Henning-Berlin GmbH, Berlin. Dr. Bergmann is member of the Executive Boards of “Waltraut Bergmann Stiftung zur Förderung der Krebsforschung” and Adrenomed AG.

Dr. rer. nat. Ute Kilger
Chief Marketing Officer

Ute Kilger has worked in the patent departments of large pharmaceutical companies for over 10 years. Ute Kilger studied chemistry at the University of Merseburg and obtained a PhD in biochemistry at the Freie Universität Berlin. She finished her training as a European patent attorney in the patent department of Boehringer Mannheim GmbH. Afterwards she was patent attorney for Roche Diagnostics GmbH in Mannheim for several years, before she joined the patent department at Schering AG in 2002. During her time at Schering AG, she was involved in comprehensive Due Diligence processes, mergers and acquisitions, and contract negotiations. In 2004 she was appointed Head of Global Patent Business Area Molecular Imaging.

Since August 2009, Ute Kilger is working as a partner at BOEHMERT & BOEHMERT in the areas of biology/chemistry/pharmaceuticals. She frequently lectures on IP protection at the University of Potsdam and at the Charité-Universitätsmedizin Berlin.

Board of Advisors

Stephan J. L. Bakker, Prof., University Medical Center Groningen, The Netherlands

Claude Bouhon, Prof., Emeritus of University of Paris XI, France

Salvatore DiSomma, Prof., University La Sapienza, Rome, Italy

James L. Jannuzzi, Prof., Massachusetts General Hospital, USA

Ute Kilger, PhD, Patent Attorney, BOEHMERT & BOEHMERT, Berlin, Germany

Alan S. Maisel, Prof., M.D., University of California, VA San Diego Health Care System, USA

Olle Melander, Prof., Malmö University Hospital, Sweden

Gerald Möller, PhD, former Chief Executive Officer at Boehringer Mannheim Group, Germany

Bernd Wegener, PhD, Board Member of German Federation of Pharmaceutical Industry, Germany

Max Wicha, M.D., Director of UM Comprehensive Cancer Center, Ann Arbor, USA

Marion Kiechle, Prof. Dr., Technische Universität München (TUM), University Hospital Klinikum Rechts der Isar, Munich, Germany

Peter A. Fasching, Prof. Dr., Universitätsklinikum Erlangen, Germany

Anton Scharl, Prof. Dr., Brustzentrum Klinikum St. Marien Amberg, Germany

Alexandre Mebazaa, Prof., M.D., PhD, Saint Louis Lariboisière University Hospitals, University Paris Diderot, Paris, France